Other Name: rhEPO

SEPO is an injectable rhEPO product manufactured and marketed by Sciprogen, which we acquired in December 2014.

Launched in 2001, SEPO has been approved by the CFDA for the treatment of anemia associated with CKD and the treatment of CIA. SEPO is included in the National Medical Insurance Catalogue as a Category B drug for the treatment of anemia associated with CKD and in eight provincial medical insurance catalogues (Fujian, Hainan, Heilongjiang, Hubei, Jilin, Liaoning, Shaanxi and Shanghai) for the treatment of CIA.

SEPO is manufactured at our Shenzhen production facilities. SEPO is offered in six dosages ranging from 2,000 IU to 10,000 IU, all of which are available in both vial format and pre-filled syringe format. SEPO and EPIAO are two of the only three rhEPO products in China approved for the 10,000 IU dosage.

SEPO was recognized as a well-known trademark by the Guangdong Administration for Industry and Commerce in 2014.

In 2014, SEPO was also exported to two countries.

In China, SEPO primarily competes with other rhEPO products offered by domestic companies. According to IMS, SEPO ranked tenth in the PRC rhEPO market in 2013 with a market share of 3.0% in terms of sales.